Biotech Values

[DewDiligence]

More on CRBU’s allogeneic CAR-T—(from Evaluate Vantage):

https://www.evaluate.com/vantage/articles/news/trial-results/caribous-allogeneic-car-meets-six-month-bar

With allogeneic Car-T projects struggling to yield lasting responses, six-month durability has emerged as something of a minimum for a patient’s remission to hit to be considered real. And yesterday Caribou joined Allogene in claiming that around half of lymphoma subjects treated with its project can develop responses that are maintained to this time point.

The 50% bar is relevant because it broadly matches what autologous Car-T therapies are capable of in this setting, and with the convenience of an off-the-shelf therapy the possible advantages are obvious. However, Caribou’s data, from the latest iteration of the Antler study of CB-010, make it clear that relapses will continue to be watched closely.

For now Caribou appears to have persuaded enough doubters with a dataset that now includes 16 patients, versus six in December. Its announcement was immediately followed by an upsized $125m equity offering, though with this being priced 20% below last night’s close today’s share price drop was unavoidable.